Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in pediatric AQP4 antibody positive neuromyelitis optica spectrum disorder
2021-006075-42Phase 2Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ravulizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change from baseline in annualized relapse rate. Started Feb 2022; status: active.
02
Drugs
ravulizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on 2021-006075-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006075-42.